Myriad Genetics, Inc. (MYGN)
USD 7.96
(0.13%)
USD 7.96
(0.13%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2022 | 88.1 Million USD | 153.04% |
| 2021 | -166.1 Million USD | -41.97% |
| 2020 | -117 Million USD | -183.39% |
| 2019 | 140.3 Million USD | 0.0% |
| 2018 | 140.3 Million USD | 238.09% |
| 2017 | -101.6 Million USD | -2978.79% |
| 2016 | -3.3 Million USD | 95.18% |
| 2015 | -68.5 Million USD | -6.86% |
| 2014 | -64.1 Million USD | 1.11% |
| 2013 | -64.82 Million USD | 37.72% |
| 2012 | -104.07 Million USD | -20.52% |
| 2011 | -86.35 Million USD | -63.91% |
| 2010 | -52.68 Million USD | 43.26% |
| 2009 | -92.84 Million USD | -46.18% |
| 2008 | -63.51 Million USD | 73.29% |
| 2007 | -237.73 Million USD | -65.75% |
| 2006 | -143.43 Million USD | -45.51% |
| 2005 | -98.57 Million USD | -99.1% |
| 2004 | -49.5 Million USD | 41.05% |
| 2003 | -83.98 Million USD | -36.33% |
| 2002 | -61.6 Million USD | -0.88% |
| 2001 | -61.06 Million USD | -69.93% |
| 2000 | -35.93 Million USD | 36.07% |
| 1999 | -56.21 Million USD | -941.01% |
| 1998 | -5.4 Million USD | 62.76% |
| 1997 | -14.5 Million USD | 5.23% |
| 1996 | -15.3 Million USD | -23.39% |
| 1995 | -12.4 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q3 | 125.4 Million USD | 24.16% |
| 2023 Q1 | 108 Million USD | 22.59% |
| 2023 Q2 | 101 Million USD | -6.48% |
| 2022 FY | 88.1 Million USD | 153.04% |
| 2022 Q4 | 88.1 Million USD | 231.2% |
| 2022 Q3 | 26.6 Million USD | 691.11% |
| 2022 Q2 | -4.5 Million USD | 94.02% |
| 2022 Q1 | -75.3 Million USD | 54.67% |
| 2021 FY | -166.1 Million USD | -41.97% |
| 2021 Q1 | 68.5 Million USD | -60.17% |
| 2021 Q2 | 82.3 Million USD | 20.15% |
| 2021 Q3 | -201.7 Million USD | -345.08% |
| 2021 Q4 | -166.1 Million USD | 17.65% |
| 2020 FY | -117 Million USD | -183.39% |
| 2020 Q1 | 173 Million USD | -19.68% |
| 2020 Q3 | 173.4 Million USD | 32.27% |
| 2020 Q2 | 131.1 Million USD | -24.22% |
| 2020 Q4 | 172 Million USD | -0.81% |
| 2019 FY | 140.3 Million USD | 0.0% |
| 2019 Q1 | 178.5 Million USD | -2.3% |
| 2019 Q2 | 140.3 Million USD | -21.4% |
| 2019 Q3 | 210.7 Million USD | 50.18% |
| 2019 Q4 | 215.4 Million USD | 2.23% |
| 2018 FY | 140.3 Million USD | 238.09% |
| 2018 Q3 | 164.7 Million USD | 262.11% |
| 2018 Q4 | 182.7 Million USD | 10.93% |
| 2018 Q1 | -28.1 Million USD | 38.24% |
| 2018 Q2 | -101.6 Million USD | -261.57% |
| 2017 Q1 | 43.3 Million USD | -54.85% |
| 2017 FY | -101.6 Million USD | -2978.79% |
| 2017 Q2 | -3.3 Million USD | -107.62% |
| 2017 Q3 | -13.9 Million USD | -321.21% |
| 2017 Q4 | -45.5 Million USD | -227.34% |
| 2016 Q4 | 95.9 Million USD | -14.6% |
| 2016 FY | -3.3 Million USD | 95.18% |
| 2016 Q2 | -68.5 Million USD | 43.15% |
| 2016 Q1 | -120.5 Million USD | 10.54% |
| 2016 Q3 | 112.3 Million USD | 263.94% |
| 2015 Q3 | -87.4 Million USD | -36.35% |
| 2015 FY | -68.5 Million USD | -6.86% |
| 2015 Q1 | -55.2 Million USD | 7.54% |
| 2015 Q2 | -64.1 Million USD | -16.1% |
| 2015 Q4 | -134.7 Million USD | -54.12% |
| 2014 Q3 | -69.8 Million USD | -7.69% |
| 2014 Q1 | -85.79 Million USD | -19.83% |
| 2014 Q2 | -64.82 Million USD | 24.45% |
| 2014 Q4 | -59.7 Million USD | 14.46% |
| 2014 FY | -64.1 Million USD | 1.11% |
| 2013 Q2 | -104.07 Million USD | 7.34% |
| 2013 FY | -64.82 Million USD | 37.72% |
| 2013 Q3 | -84.98 Million USD | 18.34% |
| 2013 Q4 | -71.59 Million USD | 15.75% |
| 2013 Q1 | -112.32 Million USD | -64.16% |
| 2012 Q4 | -68.42 Million USD | 28.42% |
| 2012 Q1 | -104.85 Million USD | 3.67% |
| 2012 Q2 | -86.35 Million USD | 17.64% |
| 2012 Q3 | -95.58 Million USD | -10.69% |
| 2012 FY | -104.07 Million USD | -20.52% |
| 2011 Q4 | -108.84 Million USD | -73.67% |
| 2011 Q1 | -67.37 Million USD | 0.43% |
| 2011 Q3 | -62.67 Million USD | -18.97% |
| 2011 Q2 | -52.68 Million USD | 21.81% |
| 2011 FY | -86.35 Million USD | -63.91% |
| 2010 Q1 | -102.14 Million USD | -69.03% |
| 2010 FY | -52.68 Million USD | 43.26% |
| 2010 Q4 | -67.66 Million USD | 45.12% |
| 2010 Q3 | -123.3 Million USD | -32.81% |
| 2010 Q2 | -92.84 Million USD | 9.11% |
| 2009 Q3 | -91.19 Million USD | -43.59% |
| 2009 Q4 | -60.43 Million USD | 33.74% |
| 2009 Q1 | -200.68 Million USD | -12.12% |
| 2009 Q2 | -63.51 Million USD | 68.35% |
| 2009 FY | -92.84 Million USD | -46.18% |
| 2008 Q3 | -230.23 Million USD | 3.16% |
| 2008 Q4 | -178.98 Million USD | 22.26% |
| 2008 Q2 | -237.73 Million USD | -66.96% |
| 2008 Q1 | -142.39 Million USD | -24.28% |
| 2008 FY | -63.51 Million USD | 73.29% |
| 2007 Q4 | -114.57 Million USD | -6.86% |
| 2007 FY | -237.73 Million USD | -65.75% |
| 2007 Q1 | -194.87 Million USD | -126.94% |
| 2007 Q3 | -107.21 Million USD | 25.25% |
| 2007 Q2 | -143.43 Million USD | 26.4% |
| 2006 Q2 | -98.57 Million USD | 7.36% |
| 2006 Q4 | -85.86 Million USD | 3.11% |
| 2006 Q1 | -106.4 Million USD | 10.27% |
| 2006 FY | -143.43 Million USD | -45.51% |
| 2006 Q3 | -88.62 Million USD | 10.09% |
| 2005 Q3 | -38.72 Million USD | 21.78% |
| 2005 Q2 | -49.5 Million USD | -2.31% |
| 2005 Q1 | -48.39 Million USD | 22.59% |
| 2005 FY | -98.57 Million USD | -99.1% |
| 2005 Q4 | -118.58 Million USD | -206.19% |
| 2004 Q4 | -62.51 Million USD | 4.55% |
| 2004 Q3 | -65.49 Million USD | 22.02% |
| 2004 Q2 | -83.98 Million USD | -79.02% |
| 2004 FY | -49.5 Million USD | 41.05% |
| 2004 Q1 | -46.91 Million USD | -10.47% |
| 2003 Q3 | -48.23 Million USD | 21.7% |
| 2003 Q4 | -42.46 Million USD | 11.96% |
| 2003 Q2 | -61.6 Million USD | 23.4% |
| 2003 Q1 | -80.42 Million USD | 17.11% |
| 2003 FY | -83.98 Million USD | -36.33% |
| 2002 Q3 | -48.51 Million USD | 20.55% |
| 2002 Q1 | -58.56 Million USD | -10.08% |
| 2002 FY | -61.6 Million USD | -0.88% |
| 2002 Q4 | -97.02 Million USD | -99.98% |
| 2002 Q2 | -61.06 Million USD | -4.27% |
| 2001 FY | -61.06 Million USD | -69.93% |
| 2001 Q4 | -53.2 Million USD | -12.35% |
| 2001 Q2 | -35.93 Million USD | 62.64% |
| 2001 Q3 | -47.35 Million USD | -31.78% |
| 2001 Q1 | -96.2 Million USD | -4.08% |
| 2000 Q2 | -56.21 Million USD | -95.33% |
| 2000 Q4 | -92.42 Million USD | -57.64% |
| 2000 Q3 | -58.63 Million USD | -4.3% |
| 2000 Q1 | -28.78 Million USD | -3.9% |
| 2000 FY | -35.93 Million USD | 36.07% |
| 1999 FY | -56.21 Million USD | -941.01% |
| 1999 Q1 | -8.3 Million USD | 52.02% |
| 1999 Q4 | -27.7 Million USD | -76.43% |
| 1999 Q3 | -15.7 Million USD | -190.74% |
| 1999 Q2 | -5.4 Million USD | 34.94% |
| 1998 Q1 | -13.2 Million USD | 20.96% |
| 1998 Q3 | -9.2 Million USD | 36.55% |
| 1998 FY | -5.4 Million USD | 62.76% |
| 1998 Q2 | -14.5 Million USD | -9.85% |
| 1998 Q4 | -17.3 Million USD | -88.04% |
| 1997 Q1 | -16.2 Million USD | -10.2% |
| 1997 Q4 | -16.7 Million USD | 16.5% |
| 1997 Q3 | -20 Million USD | -30.72% |
| 1997 Q2 | -15.3 Million USD | 5.56% |
| 1997 FY | -14.5 Million USD | 5.23% |
| 1996 Q2 | -12.4 Million USD | 51.18% |
| 1996 Q3 | -14.1 Million USD | -13.71% |
| 1996 Q4 | -14.7 Million USD | -4.26% |
| 1996 Q1 | -25.4 Million USD | 8.3% |
| 1996 FY | -15.3 Million USD | -23.39% |
| 1995 Q4 | -27.7 Million USD | 0.0% |
| 1995 FY | -12.4 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -39.45 Million USD | 323.309% |
| Applied DNA Sciences, Inc. | -5.91 Million USD | 1589.675% |
| Aspira Women's Health Inc. | -331 Thousand USD | 26716.314% |
| Biodesix, Inc. | 34.3 Million USD | -156.799% |
| BioNexus Gene Lab Corp. | -5.79 Million USD | 1620.029% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | 7188.085% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | 7188.085% |
| Bionano Genomics, Inc. | 34.88 Million USD | -152.566% |
| CareDx, Inc | -47.97 Million USD | 283.633% |
| Check-Cap Ltd. | -24.75 Million USD | 455.873% |
| Castle Biosciences, Inc. | -83.53 Million USD | 205.47% |
| DarioHealth Corp. | -7.54 Million USD | 1267.197% |
| Exact Sciences Corporation | 1.94 Billion USD | 95.481% |
| Fulgent Genetics, Inc. | -82.56 Million USD | 206.703% |
| Guardant Health, Inc. | 220.22 Million USD | 59.996% |
| ICON Public Limited Company | 3.56 Billion USD | 97.525% |
| IDEXX Laboratories, Inc. | 493.94 Million USD | 82.164% |
| Illumina, Inc. | 1.21 Billion USD | 92.743% |
| Intelligent Bio Solutions Inc. | -5.43 Million USD | 1721.674% |
| iSpecimen Inc. | -2.14 Million USD | 4202.594% |
| Standard BioTools Inc. | 46.5 Million USD | -89.438% |
| MDxHealth SA | 18.88 Million USD | -366.508% |
| 23andMe Holding Co. | -141.37 Million USD | 162.318% |
| Medpace Holdings, Inc. | -103.32 Million USD | 185.263% |
| Mainz Biomed B.V. | 349.85 Thousand USD | -25081.861% |
| ENDRA Life Sciences Inc. | -2.43 Million USD | 3711.39% |
| NeoGenomics, Inc. | 269.19 Million USD | 67.272% |
| Neogen Corporation | 735.62 Million USD | 88.024% |
| Inotiv, Inc. | 382.14 Million USD | 76.946% |
| Natera, Inc. | -200.1 Million USD | 144.028% |
| OpGen, Inc. | 11.89 Million USD | -640.841% |
| OPKO Health, Inc. | 230.68 Million USD | 61.809% |
| Psychemedics Corporation | 334 Thousand USD | -26277.246% |
| Prenetics Global Limited | -43.33 Million USD | 303.29% |
| Prenetics Global Limited | -43.33 Million USD | 303.29% |
| Precipio, Inc. | -386 Thousand USD | 22923.834% |
| Personalis, Inc. | -8.02 Million USD | 1198.23% |
| RadNet, Inc. | 1.14 Billion USD | 92.329% |
| Sera Prognostics, Inc. | -2.02 Million USD | 4457.072% |
| Sotera Health Company | 2.02 Billion USD | 95.65% |
| Neuronetics, Inc. | 2.79 Million USD | -3049.803% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 674.428% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 674.428% |
| Trinity Biotech plc | 63.73 Million USD | -38.226% |
| T2 Biosystems, Inc. | 33.8 Million USD | -160.582% |
| Twist Bioscience Corporation | -192.4 Million USD | 145.79% |
| Exagen Inc. | -12.77 Million USD | 789.79% |